Related references
Note: Only part of the references are listed.Treatment landscape of triple-negative breast cancer - expanded options, evolving needs
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
Yutian Zou et al.
NATURE COMMUNICATIONS (2022)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era
Maria Gion et al.
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting (2022)
Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer
Mi Jeong Kwon
ARCHIVES OF PHARMACAL RESEARCH (2022)
Triple negative breast cancer: Pitfalls and progress
Paola Zagami et al.
NPJ BREAST CANCER (2022)
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors
Yanyan Cai et al.
CANCER RESEARCH (2021)
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Priyanka Sharma et al.
CLINICAL CANCER RESEARCH (2021)
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer PantHER
Niamh M. Keegan et al.
CANCERS (2021)
Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors
Anna Thulin et al.
SCIENTIFIC REPORTS (2021)
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer
Komal Jhaveri et al.
CLINICAL CANCER RESEARCH (2021)
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers
E. E. Dumbrava et al.
ESMO OPEN (2021)
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Nicola Fusco et al.
FRONTIERS IN ONCOLOGY (2021)
PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway
Huayu Hu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
PI3K inhibitors are finally coming of age
Bart Vanhaesebroeck et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
The present and future of PI3K inhibitors for cancer therapy
Pau Castel et al.
NATURE CANCER (2021)
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Francis W. Hunter et al.
BRITISH JOURNAL OF CANCER (2020)
Synergistic therapeutic effect of combined PDGFR and SGK1 inhibition in metastasis-initiating cells of breast cancer
Lu Yang et al.
CELL DEATH AND DIFFERENTIATION (2020)
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Romualdo Barroso-Sousa et al.
CLINICAL CANCER RESEARCH (2020)
PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis
Ali Alqahtani et al.
CANCERS (2020)
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy
Sanxing Guo et al.
CANCER RESEARCH AND TREATMENT (2020)
Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer
Deborah L. Toppmeyer et al.
CANCER MEDICINE (2020)
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Ana C. Garrido-Castro et al.
BREAST CANCER RESEARCH (2020)
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses
Caterina Fumagalli et al.
BREAST CANCER RESEARCH (2020)
PI3K inhibitors: review and new strategies
Mingzhen Zhang et al.
CHEMICAL SCIENCE (2020)
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Olga Martinez-Saez et al.
BREAST CANCER RESEARCH (2020)
Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
Florence Coussy et al.
THERANOSTICS (2020)
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review
Angela Esposito et al.
JAMA ONCOLOGY (2019)
Targeting the PI3-kinase pathway in triple-negative breast cancer
J. Pascual et al.
ANNALS OF ONCOLOGY (2019)
PIPA: A phase Ib study of selective β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers-Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.
Juanita Suzanne Lopez et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes
C. Elfgen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Ali S. Alzahrani
SEMINARS IN CANCER BIOLOGY (2019)
Overview of the relevance of PI3K pathway in HR-positive breast cancer
N. Vasan et al.
ANNALS OF ONCOLOGY (2019)
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
M. Brandao et al.
ANNALS OF ONCOLOGY (2019)
Efficacy of PI3K inhibitors in advanced breast cancer
B. Verret et al.
ANNALS OF ONCOLOGY (2019)
Management of toxicity to isoform α-specific PI3K inhibitors
S. E. Nunnery et al.
ANNALS OF ONCOLOGY (2019)
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Neil Vasan et al.
SCIENCE (2019)
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Yan Xing et al.
BREAST CANCER RESEARCH (2019)
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
Sarika Jain et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Willemijne A. M. E. Schrijver et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Willemijne A. M. E. Schrijver et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors
Jordi Rodon et al.
Oncotarget (2018)
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Mothaffar F. Rimawi et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
B. Pistilli et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4)
M. Martin et al.
ANNALS OF ONCOLOGY (2017)
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2017)
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
Sibylle Loibl et al.
EUROPEAN JOURNAL OF CANCER (2017)
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
Mathilde Guerin et al.
EUROPEAN JOURNAL OF CANCER (2017)
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Uzma S. Asghar et al.
CLINICAL CANCER RESEARCH (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S. Loibl et al.
ANNALS OF ONCOLOGY (2016)
PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
S. Goel et al.
ANNALS OF ONCOLOGY (2016)
The PI3K/AKT Pathway as a Target for Cancer Treatment
Ingrid A. Mayer et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Jose Baselga et al.
CLINICAL CANCER RESEARCH (2016)
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer
Takashi Takeshita et al.
CANCER SCIENCE (2015)
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Mario Giuliano et al.
CLINICAL CANCER RESEARCH (2015)
Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
Katherine L. Pogue-Geile et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
Sara Tolaney et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
PI3K/AKT signaling pathway and cancer: an updated review
Miriam Martini et al.
ANNALS OF MEDICINE (2014)
Phase I dose- escalation study of buparlisib ( BKM120), an oral pan- class I PI3K inhibitor, in Japanese patients with advanced solid tumors
Yuichi Ando et al.
CANCER SCIENCE (2014)
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Cristina Saura et al.
CLINICAL CANCER RESEARCH (2014)
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis
Yi-Rong Liu et al.
ONCOTARGETS AND THERAPY (2014)
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
Brian D. Lehmann et al.
BREAST CANCER RESEARCH (2014)
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
M. Cizkova et al.
BRITISH JOURNAL OF CANCER (2013)
Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
Sherene Loi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
L-Y Huw et al.
ONCOGENESIS (2013)
Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R
D. S. Meyer et al.
ONCOGENESIS (2013)
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
J. D. Jensen et al.
ANNALS OF ONCOLOGY (2012)
GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
Jeffrey J. Wallin et al.
CLINICAL CANCER RESEARCH (2012)
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
Valentina Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Michael Untch et al.
LANCET ONCOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar et al.
CANCER DISCOVERY (2012)
Safety Profile and Clinical Activity of Single-Agent BKM120, a Pan-Class I P13K Inhibitor, for the Treatment of Patients with Metastatic Breast Carcinoma.
J. Rodon et al.
CANCER RESEARCH (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V. Serra et al.
ONCOGENE (2011)
PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer
Francisco J. Esteva et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
PIK3CA Mutations in In situ and Invasive Breast Carcinomas
Alexander Miron et al.
CANCER RESEARCH (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kevin Kalinsky et al.
CLINICAL CANCER RESEARCH (2009)
The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations
Chuan-Hsiang Huang et al.
SCIENCE (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
GJ Wu et al.
BREAST CANCER RESEARCH (2005)
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells
WH Mondesire et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
